The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …

B-cells play a major role in the immunopathogenesis of autoimmune diseases. Not only do
they produce autoantibodies, but they regulate other cell types, secrete cytokines, and …

CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …

The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the
immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a …

Recent advances in the study of CD22 indicate a complex role for this transmembrane
glycoprotein member of the immunoglobulin superfamily in the regulation of B lymphocyte …

CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically
expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma …

Immunotherapeutic agents play an increasingly important role in the treatment of B-cell
malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though …

Despite progress in the treatment of B cell disorders, novel treatment approaches are still
highly needed. CD19 is a pan-B cell marker that is recognized as a potential immunotherapy …

Purpose: The aim of this research was to further investigate the contribution of CD20 antigen
expression to rituximab activity and define the mechanisms responsible for CD20 …